Establishment and validation of survival nomogram score staging for esophageal squamous cell carcinoma patients after minimally invasive surgery combined with immune prognostic index and clinicopathological features

建立并验证微创手术后食管鳞状细胞癌患者生存列线图评分分期,该评分结合免疫预后指数和临床病理特征。

阅读:2

Abstract

BACKGROUND: Minimally invasive esophagectomy (MIE) is commonly applied in the treatment of esophageal squamous cell carcinoma (ESCC). The preoperative immune prognostic index (IPI) is considered a potential indicator for ESCC. In this study, we attempted to establish and validate a comprehensive clinical risk staging toward predicting the long-term outcome in ESCC patients after MIE through the combined application of IPI and clinicopathological features based on nomogram. METHODS: Patients diagnosed with ESCC and who were treated with MIE at our center were randomly assigned in a 7:3 ratio to two cohorts: training (n=425) and validation (n=188). Nomograms were then established according to the Cox multivariate results for the training cohort. To evaluate the predictive value and the clinical benefit rate of the nomogram, we employed the calibration curve, decision curve analysis (DCA), and time-dependent area under the curve (t-AUC). The best cut-off value obtained was applied to develop the survival nomogram-scoring (SNS) staging. RESULTS: Patients with ESCC and who underwent MIE exhibited the worse overall survival (OS) and disease-free survival (DFS) with an IPI=2 relative to IPI=0 or 1 (all P < 0.001) in the training and validation cohorts, respectively. According to the multivariate Cox analysis, we established nomograms that combined IPI with the clinicopathological features to predict the OS and DFS. The t-AUC and DCA demonstrated that the nomograms had a better predictive value and clinical benefit rate than the American Joint Committee on Cancer (AJCC) staging. Accordingly, we developed the SNS staging and found that the OS and DFS were significantly different among patients at different stages (all P < 0.001). The dynamic mortality risk rate revealed a double peak in the high-risk patients (12 and 48 months) and a single peak in the low-risk patients (24 months) and middle-risk patients (12 months), which gradually decreased over time. CONCLUSION: The SNS staging based on IPI and clinicopathological features can thus be applied to effectively evaluate the OS and DFS of ESCC patients after MIE. Our findings may facilitate the development of clinical follow-up strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。